leukemia
|
0.500 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
leukemia
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Analysis of the gene-expression patterns of leukemic subpopulations revealed that the NRAS(G12V)-mediated leukemia self-renewal signature is preferentially expressed in the leukemia stem cell-enriched subpopulation.
|
25316678 |
2014 |
leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Because the INS gene, which was also translocated, is probably located proximal to HRAS1 on chromosome 11p, it is unlikely that HRAS1 was near the chromosome 11 breakpoint or involved in this leukaemia.
|
2713271 |
1989 |
leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Both monoallelic and biallelic oncogenic NRAS mutations are identified in human leukemias, suggesting a dose-dependent role of oncogenic NRAS in leukemogenesis.
|
21586752 |
2011 |
leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Characterization of a patient with concurrent BRAF-mutant melanoma and NRAS-mutant leukemia treated intermittently with combined BRAF and MEK inhibition provides new insights into the potential clinical and molecular effects of this therapeutic strategy.
|
24795008 |
2014 |
leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis.
|
27698462 |
2016 |
leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
From 5% to 20% of patients with agnogenic myeloid metaplasia (AMM) will evolve into a terminal leukemic phase; N-RAS gene mutations are the most common gene abnormalities detected in patients with leukemia.
|
9680115 |
1998 |
leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genomic analyses failed to detect N-ras gene mutations in any of the 35 leukemias.
|
11369625 |
2001 |
leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In a patient with a BRAF(V600K)-mutant melanoma responding to vemurafenib, we observed accelerated progression of a previously unrecognized NRAS-mutant leukemia.
|
24589925 |
2014 |
leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In contrast, other activating mutations like FLT3 and NRAS mutations were very rarely detected in AML1-rearranged leukemia.
|
16254134 |
2006 |
leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Injecting Mx1-Cre, LSL-Nras(G12D) mice with the MOL4070LTR retrovirus causes acute myeloid leukemia that faithfully recapitulates many aspects of human NRAS-associated leukemias, including cooperation with deregulated Evi1 expression.
|
21163920 |
2011 |
leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
MEK1 is required for the development of NRAS-driven leukemia.
|
27741509 |
2016 |
leukemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Our observation of the mutation at codon 13 in leukaemic cell DNAs from all three cases suggests that activation of the N-ras gene is important in the development of leukaemia in some MDS cases.
|
3295562 |
1987 |
leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Since no NRAS mutations were detected among the t(8;21) samples and only 1 was found in the inv(16) group, we conclude that acute myeloid leukaemias with t(8;21) or inv(16) generally arise and progress without the involvement of NRAS mutations.
|
8599996 |
1996 |
leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The authors conclude that N-RAS mutations are not an early event preceding transformation of AA or AA/PNH to leukemia.
|
10627475 |
2000 |
leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The mutations of the N-ras gene were detected only in two cases with MDS-derived leukemia.
|
9177441 |
1997 |
leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we used single-strand conformation polymorphism analysis and an allele-specific restriction enzyme assay to investigate the frequency of KRAS and NRAS mutations in 32 pediatric leukemias with translocation of the MLL gene.
|
9523205 |
1998 |
leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These findings indicate that the N-ras mutations may not always be characterized simply by an accumulative process and that the activated N-ras gene alone is not sufficient to cause leukemia.
|
8514604 |
1993 |
leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These observations suggest that the chromosomal abnormality may precede activation of the N-ras gene in these patients, and that both the chromosomal abnormality and the activated N-ras oncogene contribute to the development of leukemia.
|
3275473 |
1988 |
leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
We compared the frequency of FLT3-length mutations (FLT3-LM), FLT3-TKD, MLL-partial tandem duplications (MLL-PTD), NRAS, and KITD816 in 381 patients with MDS refractory anemia with excess blasts [RAEB] n=49; with ringed sideroblasts [RARS] n=310; chronic monomyelocytic leukemia [CMML] n=22) and in 4130 patients with AML (de novo: n=3139; secondary AML [s-AML] following MDS: n=397; therapy-related [t-AML]: n=233; relapsed: n=361).
|
17550846 |
2007 |